Abstracts tagged "opportunistic infections"

Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Huan Huang ³, Lawrence Chang ², Xin Wang ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth Meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
Abstract Number: 2105 • 2019 ACR/ARP Annual Meeting
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Kengo Akashi¹, Sadao Jinno ², Akira Onishi ¹, Mai Yamashita ³, Yoko Nose ⁴, Takaichi Okano ¹, Yo Ueda ¹, Sho Sendo ¹, Jun Saegusa ¹ and Akio Morinobu ¹, ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ³Department of Rheumatology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan, ⁴Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan
Background/Purpose: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as a first-line agent of pneumocystis pneumonia (PCP) prophylaxis for those who receive prolonged high-dose glucocorticoids. Alternative agents can be…
Abstract Number: 2114 • 2019 ACR/ARP Annual Meeting
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Daisuke Kobayashi¹, Sayuri Takamura ², Yoko Wada ³, Takeshi Kuroda ⁴ and Ichiei Narita ¹, ¹Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, ³Niigata Rinko Hospital, Niigata, Niigata, Japan, ⁴Health administration office, Niigata University, Niigata, Niigata, Japan
Background/Purpose: Intensive immunosuppressive treatment is often required for patients with autoimmune diseases, and those who are thus treated have a high risk of opportunistic infections.…
Abstract Number: 2151 • 2017 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Opportunistic Infection during Treatment for Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Yumiko Sugiyama^1,2, Ryusuke Yoshimi^1,2, Maasa Tamura^2,3, Naoki Hamada^1,2, Hideto Nagai^1,2, Naomi Tsuchida^1,4, Yosuke Kunishita^1,2, Yutaro Soejima^1,2, Daiga Kishimoto^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^1,5, Yohei Kirino^1,2, Shigeru Ohno^1,6 and Hideaki Nakajima², ¹Y-CURD Study Group, Yokohama, Japan, ²Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Y-CURD Study Group, Yokohma, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Rheumatic Disease Center, Yokohama City University Medical Center, Yokohama, Japan, ⁶Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Although concomitant infectious diseases are the predominant causes of death in patients with polymyositis (PM)/dermatomyositis (DM)-associated interstitial lung disease (ILD), intensive immunosuppressive treatment are…
Abstract Number: 2787 • 2017 ACR/ARHP Annual Meeting
Tuberculosis, Potential Opportunistic Infections, and Other Infections of Interest in Patients with Moderate to Severe Rheumatoid Arthritis in the Baricitinib Program
Kevin Winthrop¹, Stephen Lindsey², Masayoshi Harigai³, John D. Bradley⁴, Lei Chen⁴, David L. Hyslop⁴, Maher Issa⁴, Atsushi Nishikawa⁵, Sarah Witt⁴, Christina L. Dickson⁴ and Maxime Dougados⁶, ¹Oregon Health & Science University, Portland, OR, ²Ochsner Health Center, Baton Rouge, LA, ³Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Lilly Japan K.K., Kobe, Japan, ⁶Rene Descartes University, Cochin Hospital, Paris, France
Background/Purpose: Baricitinib (bari) is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor approved in the EU for the treatment (trt) of moderately to…
Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting
Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country
Liliana Uribe Botero¹, Margarita A Saldarriaga Alvarez¹, Natalia Duque Zapata¹, Johnny Urrego¹, Oscar Jair Felipe Diaz¹, Carmen Cerón², Alejandro Uribe¹, Luis Alonso Gonzalez^1,3 and José A. Gómez-Puerta¹, ¹Medicarte IPS, Medellín, Colombia, Medellín, Colombia, ²Medicarte IPS, Medellín, Colombia, ³Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia
Background/Purpose: Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
Abstract Number: 1589 • 2014 ACR/ARHP Annual Meeting
Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis/Psoriatic arthritis (PsO/PsA) often requires treatment with systemic agents. Some of these agents are associated with infectious adverse events. Few studies have described the…
Abstract Number: 576 • 2013 ACR/ARHP Annual Meeting
Monitoring Of Opportunistic Virus Infections In Systemic Lupus Erythematosus
Lorenzo Cavagna¹, Sandra Calarota², Eva Scorletti³, Roberto Caporali⁴, Francesca Rovida⁵, Carlomaurizio Montecucco¹ and Fausto Baldanti⁵, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Molecular Virology Unit, Virology and Microbiology Department, IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ³Division of Rheumatology, University and IRCCS Foundation Policlinico S. Matteo, Pavia, Italy, ⁴Division of Rheumatology, IRCCS Policlinico San Matteo Foundation and University of Pavia, Pavia, Italy, ⁵Molecular Virology Unit, Virology and Microbiology Department, IRCCS Foundation Policlinico S. Matteo,, Pavia, Italy
Background/Purpose: due to disease characteristics and treatment approaches, systemic lupus erythematosus (SLE) patients are at high risk of opportunistic virus infections, as for example Epstein…
Abstract Number: 1308 • 2012 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
Jacques-Eric Gottenberg¹, Philippe Ravaud², Thomas Bardin³, Patrice Cacoub⁴, Alain G. Cantagrel⁵, Bernard Combe⁶, Maxime Dougados⁷, Rene-Marc Flipo⁸, Bertrand Godeau⁹, Loic Guillevin¹⁰, Xavier X. Le Loet¹¹, Eric Hachulla¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Isabelle Pane¹⁵, Gabriel Baron¹⁶ and Xavier Mariette¹⁷, ¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁵Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁶Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁷Rheumatology B Department, Paris-Descartes University, Cochin Hospital, Paris, France, ⁸Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁹Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ¹⁰Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹¹Rheumatology Department, CHU de ROUEN, Rouen, France, ¹²Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ¹⁵Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹⁶Epidemiology, Strasbourg, France, ¹⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Therapy with biological agents may be associated with opportunistic infections (OIs). Data on the occurrence of OIs in patients with RA treated with rituximab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].